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ABSTRACT
There is a high incidence of infections caused by betalactamase-producing Gram-negative micro-
organisms in Brazil. These organisms are of clinical and epidemiological importance, since their 
mobile genetic elements facilitate cross-infection. The present study was conducted in sentinel rectal 
swabs from patients admitted to a cardiac surgery hospital in Rio de Janeiro, from January through 
December 2007, in a consecutive manner. The aim of the study was to characterize the genotype and 
phenotype of these isolates from colonized patients. Biochemical tests, antimicrobial susceptibility 
tests, a confi rmatory test for the expression of extended spectrum betalactamase (ESBL) production 
and polymerase chain reaction for the blaTEM, blaSHV, CTX-M1, Toho-1 and AmpC genes were 
performed at the University Hospital of Universidade do Estado do Rio de Janeiro (UERJ). The most 
frequently isolated bacteria were Escherichia coli 9/41 (21.95%) and Klebsiella pneumoniae 14/41 
(34.1%). In 24/41 (58%), the ESBL genotype was confi rmed. The most prevalent genes in samples 
that expressed ESBL were blaTEM 13/24 (54%), AmpC 12/24 (50%), blaSHV 6/24 (25%), CTX-M1 
7/24 (29%), and Toho-1 6/24 (25%). Of these, 14/24 (58%) presented more than one genotype for the 
tested primers. In nine (37%) samples other than E. coli, K. pneumoniae or Proteus spp., the pheno-
type for ESBL was found and confi rmed by PCR. The most sensitive substrate in the approximation test 
in ESBL positive samples was ceftriaxone (83%). Fifty percent of the samples expressed AmpC were 
associated with other genes. Intermediate susceptibility to ertapenem was found in 2/41 (5%). 
Keywords: polymerase chain reaction; infection control; enterobacteriaceae infections.
[Braz J Infect Dis 2011;15(1):28-33]©Elsevier Editora Ltda.
INTRODUCTION
The Enterobacteriaceae family constitutes 
the largest and most heterogeneous group 
of Gram-negative rods of clinical impor-
tance, and includes several genera, species 
and subspecies. In humans, they can cause 
a variety of diseases, and can be isolated 
from several different sites in clinical sam-
ples.1 Many of these microorganisms pro-
duce enzymes that hydrolyze penicillins, 
cephalosporins and monobactams. The 
most frequently isolated betalactamases are 
extended spectrum (ESBL), AmpC and car-
bapenemases. ESBL are enzymes that result 
in resistance to large spectrum cephalo-
sporins (oxymino cephalosporins), penicil-
lins and monobactams, while sensitivity to 
cephamycins (cefoxitine) and carbapenems 
is preserved. Betalactamase inhibitors (BLI) 
are compounds that bind reversibly or ir-
reversibly to betalactamases, avoiding anti-
biotic degradation by them. The three most 
important compounds are sulbactam, cla-
vulanic acid and tazobactam. Some enzymes 
are resistant to the three BLI.2 AmpC beta-
lactamases are coded by plasmids, which 
may contain genes that encode resistance 
to aminoglycosides, quinolones and oth-
ers. Clinical relevant bacteria that produce 
AmpC encoded β-lactamases are the CESP 
group (Citrobacter spp., Enterobacter spp., 
Serratia spp., Providencia spp.), M. morganii 
and P. aeruginosa. It may be difficult for the 
routine clinical laboratory to identify resist-
ance patterns since this expression may be 
inducible, that is, it shows during and/or af-
ter antimicrobial treatment with β-lactams.3 
These microorganisms are sensitive to car-
bapenems, but these drugs are strong induc-
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ers of AmpC enzyme production. There is no standardi-
zation by the Clinical and Laboratory Standards Institute 
(CLSI) for the detection of these isolates.4 Phenotypic 
tests use the resistance to cephamycins as the resistance 
marker related to cephalosporins. Cefoxitin induces the 
enzyme, so a narrowing of the growth inhibition zone 
will be noticed.4 Carbapenemases are β-lactamases that 
hydrolyze carbapenems, promoting resistance to them. 
Infections caused by these bacteria are a challenge to 
treat, since carbapenems are considered the antibiotics of 
choice to treat severe infections due to ESBL producing 
strains.5,6 
The presence of carbapenemases is also found in 
Enterobacteriaceae.7,8 Patient transfer between hospitals 
has been reported as a cause of its dissemination. As 
yet, there is no consensus on which infection control 
measures need to be implemented to avoid dissemina-
tion of these bacteria. Some authors suggest screening 
tests in hospitalized patients for the detection of rec-
tal carriage.9 For K. pneumoniae, the most important 
resistance mechanism is the production blakpc carbap-
enemases.10 The gene that codifies for the blakpc enzyme 
is carried by mobile genetic elements, the transposons, 
which facilitate further resistance dissemination. The 
difficulty in detecting the blakpc gene resides in the 
fact that some bacterial strains show susceptibility to 
carbapenems within the cut-off point established for 
carbapenems, but with high minimal inhibitory concen-
trations (MIC). Therefore, they are reported as sensitive 
to carbapenems, and no infection control measures are 
applied.9 Some investigators have suggested ertapenem 
as the best susceptibility marker, as its action is not in-
oculum dependent.11 Clinical and Laboratory Standards 
Institute (CLSI) published in January 2009 recommen-
dations for samples of enterobacteria that were suscep-
tible to carbapenems with a high MIC or with reduced 
zone diameter in the disk diffusion method to be tested 
for carbapemenase resistance by the Modified Hodge 
Test (MHT).12 
The goal of the present study was to determine the 
genotype and phenotype of consecutive surveillance rec-
tal swabs isolates cultured from patients admitted to a 
cardiac surgery hospital in Rio de Janeiro, so as to review 
and adopt the necessary infection control measures.
METHODS
This study was submitted to the Ethics Committee at the 
Instituto Nacional de Cardiologia (INC) and approved 
under number 0138/01.03.07. It was a cohort study, in-
cluding all consecutive rectal swabs from patients ad-
mitted to the ICU in INC in the year 2007. Surveillance 
of patients admitted to the hospital is part of infection 
control measures routinely established by the Infec-
tion Control Committee. This surveillance model aims 
to detect patients who are colonized by multiresistant 
organisms, both Gram-positive and Gram-negative. 
Patients with risk factors for such colonization, such 
as those transferred from other hospitals or long term 
residence facilities or home care settings, or with a his-
tory of hospital admission in the previous six months, 
are submitted to collection of rectal swabs, to identify 
ESBL producing microorganisms. The patient is main-
tained under contact precaution until culture results. If 
the culture is positive, the patient, already under con-
tact precaution, has not, theoretically, served as a source 
for hospital transmission. The established protocol in 
our institution is testing exclusively for ESBL produc-
tion. Rectal swabs are cultured in selective media (Mac-
Conkey agar). If there is growth on MacConkey, a disk 
diffusion test is performed on Mueller Hinton agar. An-
timicrobials tested routinely at INC microbiology lab 
are cefepime, ceftazidime, cefotaxime, ceftriaxone and 
aztreonam. Results are given as “positive for ESBL” or 
“negative for ESBL”, and identification of the microor-
ganism is not performed.
Samples included in this study were obtained from 
frozen, stocked samples kept by the microbiology lab in 
INC, dating from January to December 2007.
INC is a public tertiary referral hospital for cardiac sur-
gery in the city of Rio de Janeiro. It has 186 beds, and is re-
sponsible for 90% of pediatric cardiac surgery in the city of 
Rio, and 80% of cardiac surgery in adults. The present study 
characterized genotipically and phenotipically 41 available 
stocked screening stool samples from patients referred or 
not from other hospitals in their admission. As part of the 
study, bacteria from stools were identifi ed in the research lab 
in UERJ. ESBL expression was confi rmed by disk diffusion 
test followed by PCR for the detection of blaTEM, blaSHV, 
CTX-M-1, Toho-1 and AmpC genes. For confi rmation of 
AmpC β-lactamase production, the samples were directly 
submitted to PCR. The primers used for PCR are shown in 
Table 1.13-15 The presence of carbapenemases was also sought 
for by the MHT in those samples showing reduced sensitiv-
ity to ertapenem. Samples from rectal swabs were not rou-
tinely identifi ed, but only tested for ESBL production. With 
the change in the world scenario, with growing prevalence 
of multiresistant Gram-negatives, and as part of the present 
aim of this study, the microorganisms isolated were identi-
fi ed and carbapemenase production sought for. This study 
also aimed to test the most prevalent resistance genes in 
these colonization samples. 
RESULTS 
In this study, 41 stool samples were included to charac-
terize antibiotic and genotypic profi le. In 30/41 (73.2%) 
ESBL phenotypic expression was found, as well as in 24/41 
Vasques, Bello, Lamas et al.
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Table 1. 
Gene Primers Product References
blaTEM F:5’-TTG GGT GCA CGA GTG GGT TA -3’
 R:5’-TAA TTG TTG CCG GGA AGC TA -3’ 503bp [13]
blaSHV F:5’-TCG GGC CGC GTA GGC ATG AT -3’
 R:5’-AGC AGG GCG ACA ATC CCG CG -3’ 625bp [13]
Toho-1 F:5’-GCGACCTGGTTAACTACAATCC-3’
 R:5’-CGGTAGTATTGCCCTTAAGCC- 3’ 351bp [14]
CTXM-1 F:5’-GACGATGTCACTGGCTGAGC- 3’
 R:5’-AGCCGCCGACGCTAATACA-3’ 499bp [14]
AmpC F:5’-CGT TTG TCA GGC ACA GTC AAA TCC A-3’
 R:5’- TTC CAC TGC GGC TGC CAG T3’ 567bp [15]
(58.5%) genotypic expression with the test primers. All sam-
ples tested susceptible to imipenem and 2/41 (5%) present-
ed intermediate susceptibility to ertapenem. Susceptibility 
to quinolones was present in 13/41(31%). Table 2 shows the 
antibiotic susceptibility pattern of the isolates. Samples that 
were shown to be ESBL positive were submitted to polymer-
ase chain reaction assays (PCR). The most frequently en-
countered genes were: blaTEM 15/30 (13/24), 50% (54%), 
AmpC 15/30 (12/24), 50% (50%), blaSHV 10/30 (6/24), 
33.3% (25%), CTX-M1 10/30 (7/24), 33,3% (29%), and 
Toho-1 7/30 (6/24), 23.3% (25%).
ESBL production was shown in strains in which testing is 
not routinely recommended. These enterobacteria present-
ed a phenotype (ghost zone) by disk diffusion testing, and 
were studied by PCR for ESBL presence. Even when a strong 
AmpC enzyme inducer was used (clavulanic acid), the sam-
ples, mostly with Enterobacter spp. (CESP group), expressed 
ESBL. Eight samples of Enterobacter sp. were identifi ed and 
presented the ESBL phenotype. In all these, AmpC expres-
sion was shown by PCR.16 Of these eight samples, six (75%) 
were categorized as within cut-off point with zone diameters 
between 17 and 20 mm for ertapenem (CLSI, 2008), and 2/8 
(25%) had intermediate sensitivity, with zone diameter of 
16 mm. The modifi ed Hodge test was negative in all tested 
samples. 
DISCUSSION
Some members of the Enterobacteriaceae family, especially 
E. coli, K. pneumoniae, Enterobacter spp. and Serratia marc-
escens, are strongly associated with health care related infec-
tions, and this is particularly true in Brazil.17 The importance 
of identifying enterobacteria and implementing infection 
control measures when resistant strains are identifi ed is 
paramount. The present study reinforces the importance of 
identifying all bacterial species that produce β-lactamases 
since colonization precedes infections in most cases involv-
ing multiresistant Enterobacteriacae, and has been identi-
fi ed as an important risk factor in hospitalized patients.3 
As expected, K. pneumoniae and E. coli predominated in 
the ESBL producing species identifi ed, as described in the 
literature.12,18,19 CLSI should prompt searching for ESBL in 
strains of Klebsiella spp., E. coli and Proteus mirabilis, but we 
found that 9/24(37%) of the identifi ed bacteria in this study 
belonged to strains which are not routinely investigated for 
ESBL even by the present recommendations.20 Data from the 
literature focus on ESBL production in isolates of K. pneu-
moniae and E. coli; we, however, also showed that these sam-
ples of ESBL producers were from the CESP group of en-
terobacteria. CLSI has tried to develop tests to validate ESBL 
production in species other than Klebsiella, E. coli and Pro-
teus. However, since the 2010 recommendations of reducing 
the cut-off point for cephalosporins so as to minimize inter-
pretation errors when reporting resistance in confi rmatory 
tests.21 In our institution, it was not an established protocol 
to identify ESBL producers in routine sentinel rectal swabs, 
since the purpose of these swabs was to recommend con-
tact precautions or not. The identity of these isolates was 
not known until the present study, where Enterobacter spp. 
was found. This served as an alert to us, and with the CLSI 
guidelines, led us to adopt a new protocol where all isolates 
are identifi ed, even in colonization samples, in order to de-
fi ne our local epidemiology and adopt appropriate infection 
control measures.12,22
Therefore, had this been a routine practice, these pa-
tients would have been placed on contact precaution meas-
ures, avoiding dissemination of carbapenemase producers 
in INC. The recognition of the fi rst case of carbapemenase 
in a patient colonized by a carbapemenase producing entero-
bacterium occurred in September 2009, and dissemination, 
β-lactamase producing enterobacteria
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Table 2. 
Sample number Bacterial species Antimicrobial resistance
25173 Escherichia coli Am;cf;ctr; st;
46150 Proteus spp. Am; cf; ctr; cip;st
59782 A Enterobacter cloacae Am; amc; tzp; cf;fox; ctr; cep;cip;st
39757 Enterobacter cloacae Am;amc;cf;fox;ctr;taz;cip;st
91876 Klebsiella pneumoniae Am; amc; cf; ctr
56467 Enterobacter spp. Am; amc; cf; fox; ctr; cip; st
3659 Escherichia coli Am; tzp; cf; ctr; cep; st
46153 A Klebsiella pneumoniae Am; cf; ctr; cep;st
28998 Enterobacter cloacae Am; amc; cf; fox; ctr; st
52548 A Klebsiella pneumoniae Am; cf; ctr;cep;cip;st
52548 B Klebsiella pneumoniae Am; tzp; cf; ctr;taz;cep; cip;st
47163 Enterobacter spp. Am; amc; tzp; cf; fox; ctr; cip; st
96412 A Escherichia coli Am; cf; ctr;
96412 B Klebsiella pneumoniae Am; cf; ctr;cep
94631 Serratia marcences Am; amc; cf; fox;cip;st; ctr
21951 Escherichia coli Am; tzp; cf; ctr; cep;st
93802 Enterobacter spp. Am; amc; cf; fox; st; ctr; taz
96368 Klebsiella pneumoniae Am; cf; ctr; taz;st; an
46177 Klebsiella pneumoniae Am; cf; taz;st
38383 Klebsiella pneumoniae Am; cf; ctr; st
28398 Proteus spp. Am; tzp; cf; cip; st; ctr
52467 Enterobacter spp. Am; amc; cf; fox; ctr; cip
39299 Klebsiella pneumoniae Am; cf; ctr; taz
41045 Proteus spp. Am; tzp; cf; fox; ctr; cep; cip;st
58251 Enterobacter cloacae Am; amc; tzp;cf; fox; tr;taz;cep;cip;st
58592 Enterobacter cloacae Am; amc; cf; fox; st; ctr
90111 Escherichia coli Am;ctx;st
69739 Escherichia coli Am; cf; ctr; cep; cip; st
69748 Escherichia coli Am; tzp; cf; ctr;cep;cip;st
40827 B Klebsiella pneumoniae Am; cf; ;ctr
54614 Escherichia coli Cf;ctr
14939 Enterobacter spp. Am; cf; ctr; st
71393 A Klebsiella pneumoniae Am; cf;ctr; st
71393 B Klebsiella pneumoniae Am; cf; ctr;cep;st; an
47750 Enterobacter cloacae Am; amc; cf; fox;ctr
20173 Morganela morganii Am; amc; cf; ctr; fox;ctr;cip;st;an
54447 Proteus mirabilis Am; cf; ctr;cip;st
26046 Klebsiella oxytoca Am; cf; taz;st
71286 Klebsiella pneumoniae Am;cf;tzp;ctr
71429 Enterobacter spp. Am; amc; cf; fox;
72947 Escherichia coli Am; cf;ctr;cip; st
Antimicrobials resistance: am, ampicillin; amc, amoxicillin/clavulanic acid; tzp, piperacillin/tazobactam; cf, cephalotin; fox, ce-
foxitine; ctr, ceftriaxone; taz, ceftazidime; cep, cefepime; cip, ciprofloxacin; st, trimethoprim-sulphamethoxazole; na, amikacin.
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culminating with an outbreak in the adult ICU, occurred in 
January 2010. This has resulted in a revised protocol, imple-
mented in January 2010, whereas all patients are screened 
for ESBL and carbapenemase producing strains in rectal 
swabs they should belong to risk groups, as mentioned in 
the methods section. The Modifi ed Hodge Test is a pheno-
typic test that may be used to detect reduced susceptibility 
to carbapenems. It has been considered sensitive and spe-
cifi c for the detection of carbapenemases by MMWR.9,23,24 It 
may be part of routine practice in microbiology labs, since 
it is neither diffi cult to perform nor expensive. However, its 
interpretation depends on the observer, as there is no stand-
ardization of its reading.9,11 For the clinical microbiologist 
and infection control team, it is important to have quick an-
swers as to whether or not patients are colonized by ESBL 
and/or by Hodge positive bacteria. However, we believe it is 
also important to further study these isolates, determining 
their species and evaluate, by molecular studies, its resist-
ance genes. For ESBL and carbapenemase production ex-
pression, the gold standard is PCR.4,14
In a study from 2006, carbapenemase producing strains 
from rectal swabs were described.8 An outbreak in Puerto 
Rico in 2008 was reported, with 39 cases of infection with 
carbapemenase producing strains, where two colonized, 
asymptomatic patients who should have been under contact 
precautions were not. These patients acted as reservoirs in 
the outbreak.9 
Inadequate antimicrobial therapy in the treatment of 
severe infections in hospitalized patients is associated with 
increased mortality, and some authors emphasize the major 
impact of non-anticipated resistance.25 In the present study, 
100% of the samples showed sensitivity to imipenem and 
2/41 (5%) showed intermediate susceptibility to ertapenem. 
Ertapenem has been used for ESBL producing strains as its 
administration is once daily and it is not active against non-
fermenters, having theoretically no impact on resistance 
induction in this group.26 However, as shown in this study, 
there is growing resistance of Enterobacteriaceae to ertapen-
em. Resistance to ertapenem was not detected by disc diffu-
sion, however two samples showed intermediate sensitivity 
in this method. 
Disk diffusion tests used for confi rmation for ESBL pro-
duction detected 83.3% for ceftriaxone, 6.6% for ceftazidime, 
and 10% for both. PCR used to broaden the epidemiological 
study showed several samples (58%) expressing more than 
one gene for the test primers, which is in accordance with the 
literature that reports that enterobacteria may carry several 
genes that encode for ESBL.5 Our study also identifi ed the 
presence of ESBL genes in strains for which the phenotypic 
test is not recommended by CLSI. This group found 30% 
(9/30) of the total samples that expressed ESBL, eight of the 
samples being Enterobacter spp. and one Serratia marcescens. 
The controversies about microorganisms other than E. coli, 
Klebsiella spp. or P. mirabilis relate to the use of BLI clavulanic 
acid. Clavulanic acid, especially for members of the CESP 
group, may act as AmpC inducer, making the recognition of 
ESBL production diffi cult and yielding false negative ESBL 
results. However, in the present study CESP group member 
expressing ESBL by the disk diffusion method, when submit-
ted to PCR for the detection of the AmpC gene, also presented 
this gene. Thus, there was no interference in the phenotypic 
expression of ESBL by the presence of the AmpC gene. 
CONCLUSION
The identifi cation of Enterobacteriaceae involved in coloniza-
tion of hospitalized patients during the study period resulted in 
greater awareness as to the presence of other resistance mecha-
nisms, not so far routinely sought for in our institution. Owing 
to the study results and analysis, new rules for microbiological 
screening and infection control measures were put into prac-
tice. In other words, testing for carbapemenase production 
and isolation precautions for patients in whom these microor-
ganisms were identifi ed was implemented. The microbiology 
lab, at the present moment, has reduced the cut-off points for 
cephalosporins, as recommended by the CLSI, 2010, but kept 
the phenotypic tests for ESBL and carbapemenases expression.
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